WO2005007090A3 - Inhibitors of the map kinase pathway - Google Patents

Inhibitors of the map kinase pathway Download PDF

Info

Publication number
WO2005007090A3
WO2005007090A3 PCT/US2004/021514 US2004021514W WO2005007090A3 WO 2005007090 A3 WO2005007090 A3 WO 2005007090A3 US 2004021514 W US2004021514 W US 2004021514W WO 2005007090 A3 WO2005007090 A3 WO 2005007090A3
Authority
WO
WIPO (PCT)
Prior art keywords
map kinase
inhibitors
interaction
kinase pathway
map
Prior art date
Application number
PCT/US2004/021514
Other languages
French (fr)
Other versions
WO2005007090A2 (en
Inventor
John Blenis
Leon O Murphy
Original Assignee
Harvard College
John Blenis
Leon O Murphy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, John Blenis, Leon O Murphy filed Critical Harvard College
Publication of WO2005007090A2 publication Critical patent/WO2005007090A2/en
Publication of WO2005007090A3 publication Critical patent/WO2005007090A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MAP kinases (e.g., ERKI/2) phosphorylate a variety of target proteins including, for example, several immediate early gene products (e.g., Fos, Myc, and Jun family proteins). Certain phosphorylation reactions require binding of the MAP kinase to the DEF domain of the target protein. Inhibitors that block this interaction may be useful therapeutics for human disease, including as antineoplastic agents. Also disclosed are screening assays useful for identifying compounds that inhibit the MAP kinase-DEF domain interaction.
PCT/US2004/021514 2003-07-03 2004-07-02 Inhibitors of the map kinase pathway WO2005007090A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48476103P 2003-07-03 2003-07-03
US60/484,761 2003-07-03

Publications (2)

Publication Number Publication Date
WO2005007090A2 WO2005007090A2 (en) 2005-01-27
WO2005007090A3 true WO2005007090A3 (en) 2009-04-09

Family

ID=34079069

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/021514 WO2005007090A2 (en) 2003-07-03 2004-07-02 Inhibitors of the map kinase pathway

Country Status (1)

Country Link
WO (1) WO2005007090A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233956B2 (en) 2008-05-06 2016-01-12 Novartis Ag Benzene sulfonamide thiazole and oxazole compounds
US9284609B2 (en) 2005-09-12 2016-03-15 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US9567644B2 (en) 2010-11-19 2017-02-14 The Regents Of The University Of Michigan RAF gene fusions

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
US7183256B2 (en) 2003-03-21 2007-02-27 Cleveland Clinic Foundation TIMP3 as VEGF inhibitor
JP4897792B2 (en) * 2005-04-20 2012-03-14 ビロメッド カンパニー， リミテッド Compositions and methods for separation of fusion proteins
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
BRPI0717651A2 (en) 2006-10-17 2013-12-24 Oncotherapy Science Inc PEPTIDE CANCER VACCINES EXPRESSING MPHOSPH1 OR DEPDC1 POLYPEPTIDES
CA2771102C (en) 2009-08-14 2019-10-15 The Regents Of The University Of California Methods of diagnosing and treating autism
GB0915736D0 (en) * 2009-09-09 2009-10-07 Cambridge Entpr Ltd Biomarkers
EP2478120B1 (en) 2009-09-17 2015-09-02 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9078913B2 (en) 2009-11-06 2015-07-14 University Of Rochester Use of human Biliverdin reductase and fragments thereof protein kinase C-δ and ERK related conditions
GB201018125D0 (en) * 2010-10-26 2010-12-08 Marealis As Peptide
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
EP3126004A4 (en) * 2014-04-02 2017-11-29 Rogne Bioscience Inc. Methods and compositions for treating inflammatory disorders
WO2015155218A1 (en) * 2014-04-08 2015-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Selective inhibitors of c-fos and their antiproliferative properties
CN105986012A (en) * 2015-01-30 2016-10-05 中国科学院上海高等研究院 Applications of critical transformation state EMT gene in preparing or screening medicines or kits for diagnosing lung cancer or in screening medicines for treating lung cancer
US10314883B2 (en) 2015-02-13 2019-06-11 University Of Virginia Patent Foundation Compositions and methods for regulating blood pressure
MX2017016329A (en) 2015-06-26 2018-08-15 Univ California Antigenic peptides and uses thereof for diagnosing and treating autism.
US11331375B2 (en) 2015-07-29 2022-05-17 University Of Virginia Patent Foundation Compositions and methods for regulating leukocyte adhesion
CN108138170B (en) 2015-08-12 2022-01-25 肿瘤疗法科学股份有限公司 DEPDC 1-derived peptides and vaccines containing the same
SG10202111399YA (en) * 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
EP3835316A1 (en) * 2019-12-09 2021-06-16 Universiteit Gent Molecules for use to treat or prevent cardiac diseases
CN113694072A (en) * 2021-08-27 2021-11-26 南京大学 Application of GGPP (gas-gas phase plasma) combination and allosteric activation of humanized FBP1 in preparation of anti-hepatocellular carcinoma drugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958721A (en) * 1993-04-07 1999-09-28 Cancer Research Campaign Technology, Ltd. Methods for screening of substances for therapeutic activity and yeast for use therein
US6475778B1 (en) * 1997-02-14 2002-11-05 Dana-Farber Cancer Institute Differentiation enhancing factors and uses therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958721A (en) * 1993-04-07 1999-09-28 Cancer Research Campaign Technology, Ltd. Methods for screening of substances for therapeutic activity and yeast for use therein
US6475778B1 (en) * 1997-02-14 2002-11-05 Dana-Farber Cancer Institute Differentiation enhancing factors and uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MURPHY ET AL., NATURE CELL BIOL, vol. 4, August 2002 (2002-08-01), pages 556 - 563 *
MURPHY ET AL., NATURE CELL BIOL., vol. 4, August 2002 (2002-08-01), pages 556 - 563 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284609B2 (en) 2005-09-12 2016-03-15 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US9233956B2 (en) 2008-05-06 2016-01-12 Novartis Ag Benzene sulfonamide thiazole and oxazole compounds
US9567644B2 (en) 2010-11-19 2017-02-14 The Regents Of The University Of Michigan RAF gene fusions

Also Published As

Publication number Publication date
WO2005007090A2 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
WO2005007090A3 (en) Inhibitors of the map kinase pathway
Jozwiak Hamartin and tuberin: working together for tumour suppression
Wulf et al. The prolyl isomerase Pin1 in breast development and cancer
Smyth et al. Measuring and interpreting the selectivity of protein kinase inhibitors
WO2004062475A3 (en) Fluorescent assays for protein kinases
ATE248170T1 (en) HIGH AFFINITY KINASE INHIBITORS FOR TARGET DETECTION AND THEIR USE
WO2006017549A3 (en) Cell-based kinase assay
WO2009067546A3 (en) Lung cancer markers and uses thereof
WO2007022241A3 (en) Novel high affinity quinoline-based kinase ligands
Chen et al. Kinetic mechanism of the p38-α MAP kinase: phosphoryl transfer to synthetic peptides
WO2006081331A3 (en) Quinoxaline derivatives as antitumor agents
DE60039059D1 (en) TRIAZINE KINASE INHIBITORS
WO2005035551A3 (en) Inhibitors of proteins that bind phosphorylated molecules
WO2005028443A3 (en) Protein tyrosine kinase enzyme inhibitors
WO2004059293A3 (en) Markers for differential diagnosis and methods of use thereof
WO2000043373A3 (en) Kinase inhibitors
WO2008128050A3 (en) Methods for identification of modulators of carm1 methyl transferase activity
Kozloski et al. Mechanistic and signaling analysis of Muc4–ErbB2 signaling module: New insights into the mechanism of ligand‐independent ErbB2 activity
BR0317284A (en) Mitogen-Activated Protein Kinase-2 Aminocyanopyridine Inhibitors
Cann et al. Measuring kinase activity—a global challenge
WO2005001114A3 (en) Screening methods
WO2004012673A3 (en) Methods and reagents relating to inflammation and apoptosis
WO1998049317A3 (en) Diagnosis and treatment of phosphatase- 0r kinase-related disorders
WO2002066681A3 (en) Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
EP1670497A4 (en) METHODS FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C-EPSILON (PKCɛ) AND METHOD OF TREATMENT OF ABERRANT GLUCOSE METABOLISM ASSOCIATED THEREWITH

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase